In-frame exon deletions of the Duchenne muscular dystrophy (DMD) gene produce internally truncated proteins that typically lead to Becker muscular dystrophy (BMD), a milder allelic disorder of DMD. We hypothesized that differences in the structure of mutant dystrophin may be responsible for the clinical heterogeneity observed in Becker patients and we studied four prevalent in-frame exon deletions, i.e. Δ45-47, Δ45-48, Δ45-49 and Δ45-51. Molecular homology modelling revealed that the proteins corresponding to deletions Δ45-48 and Δ45-51 displayed a similar structure (hybrid repeat) than the wild-type dystrophin, whereas deletions Δ45-47 and Δ45-49 lead to proteins with an unrelated structure (fractional repeat). All four proteins in vitro expressed in a fragment encoding repeats 16-21 were folded in α-helices and remained highly stable. Refolding dynamics were slowed and molecular surface hydrophobicity were higher in fractional repeat containing Δ45-47 and Δ45-49 deletions compared with hybrid repeat containing Δ45-48 and Δ45-51 deletions. By retrospectively collecting data for a series of French BMD patients, we showed that the age of dilated cardiomyopathy (DCM) onset was delayed by 11 and 14 years in Δ45-48 and Δ45-49 compared with Δ45-47 patients, respectively. A clear trend toward earlier wheelchair dependency (minimum of 11 years) was also observed in Δ45-47 and Δ45-49 patients compared with Δ45-48 patients. Muscle dystrophin levels were moderately reduced in most patients without clear correlation with the deletion type. Disease progression in BMD patients appears to be dependent on the deletion itself and associated with a specific structure of dystrophin at the deletion site. † These three authors wish to be considered as representatives of contributors to the UMD-DMD France database.
Introduction
The Duchenne muscular dystrophy (DMD) gene is the largest human gene (79 exons and 2.4 Mb). It encodes the protein dystrophin and is subject to a high number of mutations, with the majority (∼70%) being deletions of one or several exons (1) . A complete loss of dystrophin due to out-of-frame mutations leads to DMD, a severe and rapidly progressive muscular disease, characterized by early onset and wheelchair (WC) dependency before the age of 13 years (2) . In ∼1-10 for 100 000 male individuals (3) (4) (5) , the deletions do not disrupt the reading-frame, and an internally truncated dystrophin is produced, leading predominantly to Becker muscular dystrophy (BMD), an allelic disorder milder than DMD. BMD is clinically heterogeneous with some affected individuals being able to experience a near normal lifestyle and lifespan, while others lose the ability to walk in their late teens or early 20s (6) (7) (8) (9) . Cardiac involvement is a prominent feature of the disease, and heart failure is the most common cause of early death in BMD patients (10) (11) (12) (13) .
Dystrophin is a large filamentous protein of 3685 residues and a molecular weight of 427 kDa (14) that protects the sarcolemma from the mechanical stresses of muscle contraction. It belongs to the cytoskeletal family of proteins able to assemble into macromolecular structures with high numbers of protein and lipid partners (15) . Dystrophin is composed of four domains: (i) an N-terminal actin-binding domain (ABD1) (approximately exons 1-8); (ii) a central rod-like domain composed of 24 spectrin-like repeats folded in a triple α-helical coiled-coil and connected to the flanking domains by hinges (approximately exons 10-60); (iii) a Cys-rich domain, which links the cytoskeleton to the extracellular matrix via the membrane with a dystrophin-associated glycoprotein complex (approximately exons [61] [62] [63] [64] [65] [66] [67] [68] [69] ; and (iv) the C-terminal end (approximately exons [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] . We recently characterized the central rod domain using a computational approach and showed that it is organized in separate and putatively specialized functional regions (16) .
The central rod domain accounts for >76% of the protein and is the site of the great majority of the deletions that cause BMD (17, 18) , specifically deletions encompassing exons 44-51 that encode repeats [17] [18] [19] [20] . Although located in the same gene region, these in-frame deletions are associated with variable clinical severity in BMD patients. It had already been suggested that the cause of this clinical variability could be attributable to structural modifications of dystrophin (12, 19, 20) . However, this hypothesis has never been thoroughly tested.
In this study, we intended to clarify the role of dystrophin structure in the clinical heterogeneity of the BMD patients carrying different in-frame deletions in the mutational hot spot of the DMD gene, i.e. deletions of exons 45-47, 45-48, 45-49 and 45-51 . We modelled the molecular structures and analysed the biochemical characteristics of the corresponding dystrophins after introducing the deletions into a fragment that includes the repeats 16-21 (R16-21) . Concomitantly, we retrospectively collected data measuring cardiac and motor function in a large cohort of French BMD patients bearing these four deletions. A semi-quantitative assessment of dystrophin levels was also collected in about half of the patients. The analysis of clinical, modelling and biochemical data provide clear evidence that the structural characteristics of dystrophin at the deletion site are strongly associated with phenotype severity in BMD patients. Notably, Δ45-48 and Δ45-51 deletions, which exhibit structural features similar to wild-type protein at the deletion site, are associated with a slower disease progression compared with Δ45-47 or Δ45-49 deletions which both lead to profound structural modifications of dystrophin.
Results
Molecular modelling of the internally truncated proteins shows hybrid versus fractional repeats at the deletion site of dystrophin All models (Fig. 1) were assessed using PROCHECK (22) , which calculated the values of the Φ/Ψ dihedral angles of the peptide bond for each residue (i.e. the Ramachandran plot) within the atomic models. Most of the residues of the initial models were in the most energetically favoured regions while <2% of residues were in energetically unfavoured regions (Table 1 ). These last residues were situated in loops regions that are highly dynamic and thus with a structuration more difficult to predict by homology modelling. Overall, these data showed that the models were of high quality. As shown by molecular homology modelling (16) and crystallography (23) , each dystrophin repeat is composed of three helices, A, B and C, which form a triple helical coiled-coil ( Fig. 1 , inset). The four truncated dystrophin exhibited modified structures compared with the wild-type R16-21. They all bear deletions starting at exon 45, which encodes the C terminal half of repeat 17 that is therefore lacking in all studied deletion mutants. However, two types of structures were observed at the deletion site, namely hybrid or fractional repeats (18) . Hybrid repeats with structure similar to triple coiled-coil repeat structure at the deletion site were observed in RΔ45-48 and RΔ45-51 (with and without hinge 3, respectively). Fractional repeats that do not reconstitute a native triple coiled-coil repeat at the deletion site were observed in RΔ45-47 and RΔ45-49 (both with hinge 3).
To assess the stability of these models, molecular dynamics (MD) relaxation was performed. The root-mean-square deviation (RMSD; see Materials and Methods for definition) of the Cα atoms was measured and showed that the models reached equilibrium for the last 22 ns of the MD trajectory (Supplementary Material, Fig. S1 ). The repeats globally maintained their tridimensional structures as showed by their Φ/Ψ dihedral angles with an increase of residues situated in the energetically favoured regions of the Ramachandran plots ( Table 1 ). The number of residues in energetically unfavoured regions decreased substantially after the MD relaxation indicating an increase of the global quality of the models. The analysis of the fluctuations by the root-mean-square of fluctuation (RMSF; see Materials and Methods for definition) (Supplementary Material, Fig. S2 ) of each Cα atom along the sequence showed that all the models maintained their secondary structures, helices and loops. By analysing the conformational clustering (Supplementary Material, Fig. S3 ), it was evident that the models presented specific points of flexibility shown by arrows in Figure 2A . A flexibility spot was located for the R16-21 wildtype model at the junction between the repeats 18 and 19. Remarkably, the flexibility of the two fractional repeats was enhanced at the deletion sites themselves, indicating that these sites represent points of structural weakness. This contrasted with the two deleted proteins exhibiting hybrid repeats, as the RΔ45-48 structure showed flexibility at the hinge 3 region, while RΔ45-51 exhibited a remarkably stable structure (no arrow).
Molecular descriptors of the truncated dystrophins compared with wild type
The electrostatic potential and molecular hydrophobicity potential (MHP) profiles of the truncated dystrophins were profoundly modified compared with wild-type dystrophin. The electrostatic potential at the C-terminal region of the new junction site differed dramatically from one protein to another ( Fig. 2B ), without specific variations corresponding to hybrid or fractional repeats. The sequence predicted isoelectric point pI increased from 5.38 for the wild type to 6.32 for the RΔ45-51 ( Fig. 2C) showing that an identical N-terminal region was joined to a C-terminal region with increasing cationic properties as the deletion size increased. In contrast, the variations in the MHP were related with the hybrid or fractional structure type at the deletion site ( Fig. 2D and E). Clearly, a higher hydrophobic surface was exposed to the solvent in fractional repeats compared with hybrid repeats. In the fractional repeat-containing proteins, whether composed by small helices (RΔ45-47) or by a double coiled-coil (RΔ45-49), hydrophobic residues normally buried in the wild-type repeats were largely exposed to the surface. For the hybrid repeatcontaining proteins, the hydrophobic residues buried in the wildtype protein remained buried even though the facing residues inside the coiled-coil were modified due to the deletions.
Biochemical characterization of wild-type and truncated dystrophin
To understand how the structure modifications observed on the molecular models could be related to the biochemical and Repeats are coloured and numbered according to the alignment from Winder (21) . The green diamond represents the hinge 3. Molecular homology models are shown on the right of the schematic representation of proteins (cyan: R16, purple: R17, yellow: R18, grey: R19, red: R20, orange: R21). An inset shows that a tandem repeat is made of three helices (A-C) joined by loops and structured in a coiled-coil; the continuity of the filament is obtained by the common helix containing the C-helix of the first repeat followed by the A′-helix of the following repeat. In the R16-21 model, each wild-type repeat has three α-helices gently wrapped in a coiled-coil. This filamentous structure is interrupted by the presence of hinge 3 in green. Models of the four truncated proteins are presented with the repeats coloured as in the wildtype R16-21. The truncated proteins all bear deletions starting at exon 45, which encodes the C-terminal half of repeat 17. The RΔ45-47 protein lacks part of repeats 17 and 18 and forms a structure clearly different from a true repeat at the site of the deletion. This incomplete repeat is known as a 'fractional repeat'. RΔ45-48 is lacking part of repeat 17, all of repeat 18 and part of repeat 19 and a structure similar to a true repeat is formed at the site of the deletion, with three helices forming a new coiled-coil called 'hybrid repeat'. RΔ45-49 is truncated from the middle of repeat 17 to the middle of repeat 19, and the two remaining parts of repeats 17 and 19 form two helices wrapped in a double coiled-coil; as the third helix of a conventional repeat is lacking in this mutant, the directionality of the molecule at the junction with hinge 3 is changed. This mutant therefore bears a 'fractional repeat' with a non-filamentous topology. RΔ45-51 lacks part of repeat 17 and all of repeats 18 and 19 and hinge 3; the remaining parts of repeat 17 and of repeat 20 make a 'hybrid repeat'. After MD 99.1 1.0 0.6 *, ** and ***corresponding to the classical Ramachandran core and allowed *, generously allowed ** and disallowed *** regions.
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Truncated proteins are folded into coiled-coils like wild-type dystrophin
To examine the effect of the deletions on the secondary structure of dystrophin, the wild-type and truncated dystrophins were analysed using circular dichroism (CD). All of the structures had typical CD spectra with two minima at 208 and 222 nm. The values at 222 nm indicated α-helix contents that ranged between 50 and 75%. Interestingly, the CD spectra showed that the ratio of the molar ellipticity at 222 and 208 nm was ≥1 for all proteins, meaning that all the proteins were folded predominantly into coiled-coils (24) (Fig. 3B ).
The truncated proteins remained highly stable compared with wild-type dystrophin
To determine if the deletions induce modifications in stability, thermal heating was followed by CD at 222 nm, and chemical denaturation by urea was followed by tryptophan intrinsic fluorescence. Thermal heating and urea denaturation revealed typical sharp two-state transitions for all of the proteins. The highest thermal mid-denaturation at 66 ± 0.8°C was recorded for wildtype R16-21. Similar values were observed for the truncated proteins RΔ45-47 and RΔ45-48 at 65°C, and lower values at 61°C were measured for RΔ45-49 and RΔ45-51 (Fig. 3C ). The wild-type R16-21 protein displayed a mid-denaturation at 5.2  urea. A similar behaviour was observed for the truncated protein RΔ45-47, while mid-denaturation was achieved with lower urea concentration for the three other proteins (4.9-5  of mid-denaturation) ( Fig. 3D ). However, the wild-type protein exhibited the highest stability, indicating that protein length and the presence of hinge 3 do not preclude stability. We can conclude that the two truncated proteins RΔ45-47 and RΔ45-48 were roughly as stable as wild-type R16-21, whereas the two shorter truncated proteins showed slightly decreased stability compared with the fulllength fragment. However, compared with point mutations that modify the sequence, these four proteins obtained by joining non-neighbouring regions of the wild-type protein were highly stable, consistent with previous studies demonstrating that this region of the dystrophin central domain is highly stable compared with the more proximal region such as this of repeats 1-3 (25) and remained highly stable even after the exon coded sequence deletions.
Refolding properties after urea denaturation are highly modified in the truncated dystrophin fragments compared with the full-length R16-21 protein Refolding after denaturation is a critical dynamic parameter. Refolding after 8  urea denaturation of the full-length and the three truncated proteins RΔ45-47, RΔ45-49 and RΔ45-51 was described by mono-exponential fits. The fastest mono-exponential refolding rate constant at 10.6 ± 2.9 s −1 was observed for the RΔ45-51 truncated protein (P < 0.0001) ( Fig. 3E ). The two other truncated proteins RΔ45-47 and RΔ45-49 displayed slower refolding rate constants of 4.3 and 3.0 s −1 , respectively. Interestingly, the refolding of RΔ45-48 was better described by two exponential components, one corresponding to a fast phase at 12.4 ± 4.4 s −1 and one to a slower phase at 2.3 ± 0.6 s −1 , each of them contributing approximately half of the total amplitude. The fast component was similar to the refolding rate constant of the truncated protein Δ45-51, and the slow rate constant was the slowest rate reported. The refolding rate constant of wild-type R16-21 was intermediate at 5.7 ± 0.7 s −1 . This value was significantly different from all other values, indicating that refolding is not slowed by the length of the protein. However, the fastest value was reported for the shorter truncated protein RΔ45-51, the only fragment lacking hinge 3, indicating that the presence of hinge 3 could slow down the refolding process. Clearly, the two truncated proteins RΔ45-47 and RΔ45-49 display slower global refolding than the other truncated proteins. The refolding rates of the truncated proteins were linearly and inversely correlated with the increases in the percentage of the hydrophobic surface exposed to solvent (R = 0.98, not shown). Indeed, the solvent exposure of some hydrophobic residues that were buried in the wild-type protein slowed down the refolding process. The refolding rates and MD data suggested that hybrid and fractional repeats could be distinguished by their dynamic properties. The refolding rates indicated that the fractional repeats required additional time to find the correct fold compared with the wild-type and to hybrid repeat-containing proteins. These observations were in agreement with the MD results, which indicated that fractional repeats had topologies and properties far different from those of the wild-type and hybrid repeat-containing proteins.
Age of DCM onset and of WC dependency of the BMD patients
From an initial cohort of 251 French patients carrying one of the four studied deletions Δ45-47 (127 patients), Δ45-48 (90 patients), Δ45-49 (31 patients) and Δ45-51 (3 patients) ( Table S1 ). Our data showed a significant difference towards earlier DCM onset in Δ45-47 BMD patients (median age of 27 years) compared with Δ45-48 patients (median age of 38 years, P = 0.031) or Δ45-49 BMD patients (median age of 41 years, P = 0.042) ( Fig. 4A ). In addition, we observed that WC dependency exhibited a clear trend toward affecting Δ45-48 BMD patients at an older age than Δ45-47 BMD patients, with a delay of 11 years (median ages of 49 and 38 years, respectively), although this difference did not reach statistical significance (P = 0.082) ( Fig. 4B) . Conversely, Δ45-49 BMD patients became WC confined at a similar median age (35 years) as Δ45-47 patients (38 years, P = 0.416) but 14 years earlier than Δ45-48 patients (49 years, P = 0.029). These differences clearly indicated that the severity spectrum was shifted toward slower disease progression for Δ45-48 BMD patients compared with Δ45-47 and Δ45-49 BMD patients. Δ45-51 patients could not be discussed here as none of the three patients in the original cohort were WC confined or DCM affected.
Dystrophin expression levels in BMD patients
When available in this retrospective cohort study, dystrophin amounts from western blots (WBs) were classified into four levels (normal, high, medium and low). Data were available for 79 of the 239 patients bearing one of the four deletions in the initial cohort and showed that most of them displayed a medium level of dystrophin, while the sixth of patients displayed low, high or normal levels for each of the deletions (Fig. 4C ). When considering only the patients with DCM or WC bound, they also displayed mostly (Fig. 4D ).
Discussion
By combining several approaches including (i) in-depth structural and biochemical investigations of truncated dystrophin molecules and (ii) clinical assessment in large subsets of French BMD patients with identical mutations, we provided clues about the role of the structure of dystrophin at the deletion site on disease progression in patients carrying in-frame deletions in the central rod domain of the protein. Clearly, refolding rates and molecular simulations data suggested that hybrid and fractional repeats could be distinguished by their dynamic properties. The heterogeneity of the BMD phenotype has long been investigated. Whereas in-frame deletions in the N-terminal actin-binding domain or in the CYS-rich domain were reported to result in a more severe clinical outcome (6, 17) , phenotype in patients carrying deletions in the central rod domain of dystrophin was more variable, ranging from isolated elevated blood creatine phosphokinase and cramps to classical BMD (6, 9, 26) . Although the reasons for this variability are not fully understood, it is likely that both levels and functionality of the internally deleted dystrophins play a significant role (27) (28) (29) .
Most BMD patients have reduced dystrophin expression levels, the milder phenotypes being associated with the higher expression levels (27) . Thus, as high as 75% of normal dystrophin expression is found in patients with the very mild Δ45-51 deletion (27, 30) , and asymptomatic patients have significantly higher dystrophin expression levels compared with symptomatic BMD patients (26, 27, 31) . In our cohort, the majority of BMD patients were classified as having medium level of dystrophin expression. However, dystrophin amounts were heterogeneous between patients carrying different deletions but also between patients carrying the same deletion as previously shown (6, 8, 26, 27, 30, 32, 33) , and did not correlate with the age of onset of DCM or of WC dependency. Measuring dystrophin levels accurately remains highly challenging (34) and the levels may be variable within a single myofiber, between adjacent myofibers and muscle biopsies. It has also been proposed that at expression levels <75% and >30%, the structural characteristics of the internally deleted dystrophins could play a significant role in the phenotype (35) . This assumption was consistent with a recent study showing that there is no linear correlation between dystrophin levels and disease severity in BMD patients, notably those carrying a Δ45-47 deletion: as long as dystrophin level is above a threshold (estimated to be ∼10%), the mutation is likely an important factor in determining disease severity (33) .
Previous studies that aimed to explore the underlying rationale of clinical variability in BMD patients were mostly based on the analysis of heterogeneous groups of patients carrying different types of deletions even though located in the same gene region: patients with distal versus proximal deletions or in the centre of the dystrophin central rod domain (6,8,26,32), those Table S2 ). The number of patients per class and per deletion type were reported. with deletions ending at specific exons (12, 31) or with deletions including or omitting hinge 3 (12, 36) . Very often patients were relatively young and still ambulatory, and the cardiac status was not reported. Overall, the obtained data suggested that the central region is not completely homogenous with respect to function, but did not allow to support a clear view of genotypephenotype correlations in BMD patients having deletions in the central rod domain of dystrophin. The methodology used here to address this question was based on the retrospective analysis of large subsets of BMD patients bearing identical deletions for whom two readily comparable and robust items as markers of disease severity (age of DCM and WC dependency) could be obtained. A comparison analysis was performed between clinical outcome in patients bearing Δ45-47, Δ45-48, Δ45-49 and Δ45-51 deletions and the predictive functionality of the truncated proteins based on the molecular properties of hybrid versus fractional repeats at the deletion site compared with wild type. The concept of hybrid repeat is reminiscent of the phasing of the repeats in mini-or microdystrophins studied by Harper et al. (37) . They showed that the mini-dystrophin ΔH2-R19 containing eight perfectly phased repeats significantly improved mdx mouse muscle function compared with the closely related construct with a deletion of the exons 17-48. This deletion was originally observed in a patient (38) and contains 'non-phased' repeats that give rise to a fractional repeat according to our predictions. Specific attention was drawn to repeats phasing in the design of the subsequent studies with mini-and micro-dystrophins in mdx mouse or grmd dog (39) (40) (41) . The most popular micro-dystrophin is the ΔR4-R23/ΔCT which is perfectly phased (42, 43) . However, the mini-dystrophin ΔH2-R19 was reported to be prone to aggregation in an in vitro assay (44) emphasizing the idea that the presence of non-native inter-repeat junction could partly compromise the dystrophin function. Quite differently, the presence of hybrid or fractional repeats at the deletion site (19, 20) are due to the fact that the Bhelices of all the repeats except repeat 14 are encoded by two successive in-frame exons, with their boundaries precisely aligned with the third heptad of the B-helices (18) . Thus, a deletion that maintains the coding of a B-helix by two exons around the deletion site allows for the formation of a hybrid repeat similar to a true repeat. This type of deletion maintains the heptad pattern of the residues along the primary sequence (21) and allows hydrophobic residues to be localized inside the coiled-coils which favours a fast refolding. In contrast, in case of a deletion that leads to a fractional repeat, hydrophobic residues are not folded inside a coiled-coil but remain accessible to the solvent, slowing down the refolding process and constituting sites of weakness in dystrophin. Both hybrid and fractional repeats at the deletion sites did not decrease dramatically the protein stability indicating that overall the dynamical properties were of highest importance for the function of dystrophin. This was not striking since dystrophin is primary involved in the resistance to the stress of elongation in muscle cells (45, 46) . However, the deletions that lead to hybrid repeats had the least impact on the structure of dystrophin, even if hinge 3 was also deleted. Kaspar et al. (12) anticipated the rule of hybrid versus fractional repeats, which they called inphase and out-of-phase repeats, respectively. They suggested that the topology of the truncated protein produced by Δ45-47 reversed the direction of the filament. In contrast, here we showed a topology that remained filamentous in RΔ45-47, even though there was an incomplete coiled-coil structure at the deletion site. Indeed, in Kaspar et al. previous study, mutated models were manually constructed considering that each repeat contained both a long and a short helix. This was not in line with the clear features now available from the X-ray crystals of spectrin and dystrophin repeats, which showed that repeats are made of three helices gently wrapped in a coiled-coil (47) . Therefore, our data argued for a conserved filamentous structure in RΔ45-47 and a profoundly modified topology of RΔ45-49. Finally, we showed here that it is not the absence of hinge 3 that correlated with the age of onset of DCM (12) but the structure of these truncated dystrophins.
According to the structural and dynamic modifications observed in the various internally truncated mutants studied, we suggested a functional classification such that R16-21 > RΔ45-51 > RΔ45-48 > RΔ45-47 ∼ RΔ45-49, that is partly dependent on the presence of hybrid versus fractional repeats at the deletion sites.
Is this classification relevant at the biological and clinical levels?
The analysis of our cohort of patients allowed clear trends for cardiac and/or motor severity to be established depending on the truncated protein structure. We showed that severity gradation among the four most frequent BMD deletions increases from Δ45 to 51, through Δ45-48 and up to Δ45-47 and Δ45-49, with Δ45-48 patients being affected by DCM 11 years later than Δ45-47 patients and patients with Δ45-47 and Δ45-49 being at risk to be WC-dependent 11-14 years earlier than patients with Δ45-48. These observations strongly correlated with the presence of hybrid repeats at the deletion sites in the RΔ45-51 and RΔ45-48 truncated proteins and with the presence of fractional repeats at the deletion sites of the RΔ45-47 and RΔ45-49 truncated proteins. Because RΔ45-51 is the truncated protein the most similar to wild type, it is tempting to correlate this similarity with the characterization of Δ45-51 as a clinically very mild deletion (48) with a dystrophin expression level of ∼75% of wild type (27, 30) . The lack of symptoms may explain why such a small number of Δ45-51 carriers was present in the UMD-DMD database. Although Δ45-48 displayed a hybrid repeat, the increased flexibility of this variant compared with the wild-type and Δ45-51 proteins could partly impair the binding of the actin-binding domain 2 (repeats 11-17) to filamentous actin (49) thereby explaining why the Δ45-48 phenotype is so different from the very mild phenotype of Δ45-51. The Δ45-47 and Δ45-49 deletions lead to fractional repeats at the deletion site, which we demonstrated to constitute structurally weakened sites compared with hybrid repeats. Whether the dynamic properties associated with the hybrid or fractional repeats are relevant in vivo remains speculative, but the folding of this long filamentous protein in vivo is probably a rather complex process, and thus deletions that partly impair or slow down this process could be deleterious.
These results reinforced the idea that the 'phasing' of the repeats provides improved function to truncated dystrophin (12, 19, 20, 37, 44) . This hybrid repeat phasing appears to be essential for the function of dystrophin as a molecular shock absorber, protecting the membrane from the stresses of contraction (45, 46, 50) . In contrast, the fractional repeats are less able to protect membrane from the stresses due to their structurally weakened deletion sites.
Single-exon reported BMD deletions produce fractional repeats (18), although some of them have been associated with mild phenotypes, which is not in agreement with the results of this study. The structures of such truncated dystrophins remain to be studied in detail, and the results could depend on the region of the central domain of dystrophin involved in. Indeed, the proximity of a hinge, such as for the deletion of exon 16, or the loss of the binding motif for an interacting partner, could also play a role in the severity of the resulting phenotypes (51, 52) . In that sense, the region covering repeats 16-21 was involved in nNOS binding (53, 54) . For patients with the mild deletion Δ45-55 (55) , the mislocalization of nNOS was a worsening factor (56) even though this deletion was predicted to lead to a hybrid repeat structure of dystrophin.
This showed that other factors are likely able to modulate the severity of the phenotype associated with a deletion leading to a hybrid repeat-containing protein, and may also account for the intra-and intergroup variability. These factors may include cisacting elements such as spontaneous alternative splicing events occurring in a fraction of dystrophin transcripts (57) , the presence of non-synonymous SNPs, notably those reported in the exons encoding the central rod domain of the protein (58), posttranscriptional regulation by microRNA (59) , but also other genetic modifiers of disease severity (60) (61) (62) (63) .
In conclusion, our findings further support a significant role of the structure of the internally truncated dystrophins produced by in-frame deletions in the central rod domain of dystrophin in determining disease severity in BMD patients. We showed that the severity of the BMD phenotype could be regarded as deletion specific. Indeed, exon deletions leading to hybrid repeats should lead to more favourable clinical outcomes than deletions leading to fractional repeats. This primary factor could be further modulated by the presence or absence of a binding partner, the presence of specific SNPs that may slightly alter the function of the dystrophin protein or by factors modulating the expression such as microRNA or by SNPs. From a pragmatic point of view, our study should help caregivers to anticipate the clinical disease course in a patient carrying a given deletion based on the structure of the resulting truncated dystrophin. Exon skipping is a promising therapy that aims to convert the severe DMD into the milder BMD phenotype by skipping one or several exons in order to restore the reading-frame (28, (64) (65) (66) . Our work indicates that exon skipping will not produce a normal dystrophin and that some isoforms generated by this approach will be more functional than others. Indeed, restoring the reading-frame would not stabilize but rather slow down disease progression depending on the induced in-frame deletion. A better knowledge of the functionality of the different isoforms of dystrophin is thus of critical importance for predicting the extent of functional benefit that any given patient may have from the exon skipping strategy. It is worth mentioning that exon skipping aiming at generating a deletion of exons 45-51 could be also highly valuable for the most severe BMD deletions. Overall, preservation of repeat phasing is a critical determinant of functional outcome of newly synthetized proteins in patients that should be considered in various therapeutic approaches, in particular micro-or mini-dystrophin gene transfer strategies (28) .
Materials and Methods
In silico analysis Molecular homology modelling was used to generate models of the four truncated dystrophins to compare them with the wildtype R16-21 fragment previously obtained (67) . For each truncated dystrophin, previously described models were used (18) and were lengthened by native repeats added at the C-terminal end (16) .
MD was essentially performed similarly to our previous work (16) . To simulate our systems with water and ions, we used the program NAMD 2.8 (68) and the CHARMM27 force field (69-72). The initial models were oriented along the z-axis and then solvated in rectangular water boxes generated using the Solvate plug-in of VMD (73) . We thus ensured that there was a 25 Å thick layer of TIP3P water in the x directions and a 35 Å thick layer in the y and z direction. Subsequently, the VMD plug-in Autoionize was used to place ions randomly to neutralize the system. To adjust the position of the solvent (water and ions) around the molecules, each system was energy minimized for 10 000 steps using the conjugate gradient method while restraining the solute atoms with a 25 kcal mol −1 Å −2 harmonic restraint.
The entire system (solvent and solute) was then subjected to another 10 000 steps of energy minimization to relieve any major stresses, followed by a slow heating to 310 K at constant volume over a period of 50 ps. The equilibration and production phases were performed for 40 ns for R16-21, 35 ns for Δ45-48 and 30 ns for the three other molecules applying periodic boundary conditions and using a 2 fs time step and the SHAKE algorithm. Van der Waals interactions were computed using a cut-off distance of 12 Å with a switching function starting at 10 Å, while long-range electrostatic forces were calculated using the particle-mesh Ewald method with a grid density of 1 Å − 3 . To further reduce the cost of computing full electrostatics, a multiple-time-stepping procedure was employed to calculate long-range electrostatics every 4 fs. Berendsen baths were used to maintain the system temperature and pressure at 310 K and 1 atm, respectively.
The RMSD (in nm) compares the mean positions of the αcarbon atoms (Cα) of the peptide bond formed between the αcarboxyl group of one residue and the α-amino group of the next one in the protein (74) . RMSD is used to measure the spatial deviation of all the Cα of the protein model during the time course of the MD compared with the initial model. It was calculated to determine the equilibration phase (i.e. when the RMSD becomes constant signifying that the model no more changes) and the last 22 ns of trajectories were kept for the analysis of all simulations ( Supplementary Material, Fig. S1 ). The RMSF (in nm) reports the mean fluctuation of the position of each Cα during the MD trajectory. This indicates the sites which are highly dynamical (high RMSF) compared with sites which are rigid (low RMSF) ( Supplementary Material, Fig. S2 ). To extract representative structures, the coordinate frames from the trajectory were clustered using the K-means algorithm. After testing different values, we chose to split the trajectory into three clusters (74) . MHP were computed by the Platinum server (75, 76) using the Ghose forcefield parameters. Electrostatic potentials were computed with the program APBS (68) using the Charmm forcefield and 50 m concentrations for both sodium and chloride ions.
Biochemical analysis

Materials
The pGEX-4T-1 plasmid vector, GSTrap™ HP column were purchased from GE Healthcare. The E. coli BL21(DE3) bacteria were supplied by Invitrogen and restriction enzymes by New England Biolabs.
Cloning, expression and purification of proteins
The plasmid pTG11025 harbouring the cDNA for the Dp427 m muscle isoform of human dystrophin (NCBI Nucleotide Data Base NM-004006, provided by S. Braun Transgene, France) was used as a template for PCR amplification of fragments. The four truncated dystrophins resulting from deletions of exons 45-47, 45-48, 45-49 and 45-51 were introduced into a fragment of dystrophin recovering repeats R16-21 (Table 1) . This choice was guided by the desire to maintain the same N-and C-terminal ends for all of the deletions and an entire repeat at each end, i.e. repeat 16 at the N-terminal end and repeat 21 at the C-terminal Human Molecular Genetics, 2015, Vol. 24, No. 5 | 1275 end, even in the presence of internal deletions. The presence of the N-and C-terminal ends would be indispensable for maintaining the true folding of the fragment (77) . The construct was generated by PCR and cloned into pGEX-4T-1 vector using BamHI and XhoI restriction sites as previously described (25, 67) . For exondeleted constructs, the exon 48/repeat 21 fragment to exon 52/repeat 21 fragment was generated by PCR amplification with an 'exon' primer including a BspTI restriction cassette at the 5′ end and R21 primer (see Supplementary Material, Table S1 for the primers). Products were cloned into the wild-type construct using BspTI (end of exon 44) and XhoI restriction sites, resulting in exon deletion. All the constructs were checked by a Big Dye terminator sequencing procedure. Recombinant proteins were expressed as GST-tagged proteins in the protease-deficient E. coli BL-21 strain. Cultures were performed at 37°C in LB medium supplemented with 50 µg/mL of ampicillin. The protein expression was induced by 0.5 m IPTG addition for 4 h. Cells were harvested by centrifugation at 2500 g for 20 min.
The wild-type R16-21 was expressed as a soluble protein, whereas all truncated proteins were produced as inclusion bodies. All proteins were finally obtained as soluble forms after solubilization with N-lauryl-sarcosine (0.1%), affinity chromatography and further purification either with hydrophobic chromatography (RΔ45-47 and RΔ45-48) or not (RΔ45-49 and RΔ45-51). Exclusion chromatography performed at the end of the purification process showed that the proteins were all monomeric. Proteins were concentrated in a Tris 20 m, pH 7.5, buffer containing NaCl 150 m, EDTA 0.1 m and glycerol 5% (TNEG buffer) using centrifugationbased concentrators and concentration was determined by spectroscopy at 280 nm and using theoretical molar extinction coefficients.
CD and fluorescence analysis of the purified proteins CD was performed with a JASCO J-810 (Nantes, France) spectropolarimeter with protein concentration of ∼2.5 µ against the TNEG buffer. Spectra were acquired in the range 200-250 nm at 20°C with a path length of 0.2 cm. The percentage of α-helix was obtained using a 100% α-helix value of −36 000 deg cm 2 dmol −1 at 222 nm as previously described (78) . Thermal unfolding was followed at 222 nm with temperature increase of 1 deg/min from 15 to 85°C. As partial refolding after heating at 70°C was observed showing that denaturation was reversible, CD signal was fitted to a two-state transition as previously described (78) .
Tryptophan fluorescence spectra of the five proteins at 0.5 µ in TNE buffer were recorded on a Fluorolog spectrofluorimeter (Horiba Jobin-Yvon, Longjumeau, France) at 295 nm excitation wavelength at 20°C. After appropriate buffer correction, emission spectra of non-denatured proteins were obtained. Urea unfolding was performed by incubating proteins with urea from 0.5 to 8  in TNEG buffer with 0.1  steps for 2 h before fluorescence measurement. The maximum wavelength (λ max ) and the intensity of fluorescence were measured from the emission spectra. Reversibility of the denaturation was checked by 10-fold dilution of the 8  urea-treated protein and by observing similar spectra of this diluted and native protein. The analysis of the denaturation was analysed as previously described (25) .
Stopped-flow data were recorded on a stopped-flow BioLogic SFM-3, MOS 250 (Grenoble, France) device with a dead time of 2.2 ms. Proteins were diluted in 8  urea 2 h before refolding measurements. As a first control, the urea denatured proteins were diluted 10-fold in TNE and their tryptophan fluorescence recorded. Each protein was able to refold with the same tryptophan fluorescence spectrum after renaturation, and therefore, the refolding after 8  urea denaturation could be used to follow the refolding by stopped-flow fluorescence. The refolding reactions were initiated at 20°C by 10-fold dilution of the urea-treated proteins in TNEG buffer giving final protein concentrations of 0.25 µ. The time dependent of tryptophan fluorescence changes were monitored at excitation and emission wavelengths of 295 and 345 nm, respectively. Curves were derived from the averages of at least 10 individual kinetic data points after subtraction of the background urea buffer signal. The refolding rate constants were obtained by fitting the data with mono-or biexponential functions.
BMD patient cohort
This is a retrospective study using the national UMD-DMD France database (17) which collected data of DMD and BMD patients identified since >20 years. Two hundred and fifty-one BMD patients carrying one of the four in-frame deletions (Δ45-47, Δ45-48, Δ45-49 or Δ45-51) were retrieved from the database ( Table 3 ). Only the patients older than 16 were further considered for the study. The comparison of disease severity between the four groups was based on two clinical criteria: the age of DCM onset (defined as the age when a left ventricular ejection fraction value ≤55% as determined by echocardiography was observed) and the age at permanent WC use. To avoid bias in our analysis, we did not include patients with non-permanent WC due to the difficulty in quantifying this criterion (duration of WC use, use inside or outside the home, maximal walking distance) from one patient to another. Overall, 106 patients had definite DCM and/or were WC users with the deletions Δ45-47, Δ45-48, Δ45-49 and 19 of which displayed both DCM and WC use (Supplementary Material, Table S2 ). No patient with DCM or WC dependency was found in the subgroup of three BMD patients with Δ45-51. Furthermore, we collected data of dystrophin WB analysis using DYS1, DYS2 and DYS3 antibodies (79) performed during the diagnostic approach for 47 over the 106 patients. A semi-quantitative evaluation by visual inspection of dystrophin expression level was done. For each patient, dystrophin amounts were compared with control muscle extracts in three conditions, no dilution and 1/2 and one-third dilutions. The levels were then visually categorized into four amount classes: normal (∼70-100% of control), high (∼50-70% of control), medium (∼10-50% of control) and low (<10% of control) (Supplementary Material, Table S2 ).
Supplementary Material
Supplementary Material is available at HMG online.
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